OneMedNet Partners with Risorius to Advance EEG-Based Digital Biomarkers

The strategic data licensing agreement will support OneMedNet's expansion and Risorius' R&D efforts.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

OneMedNet Corporation, a leading provider of regulatory-grade real-world data, has announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms. The partnership will provide Risorius with access to large-scale electroencephalography (EEG) and polysomnography (PSG) waveform data paired with clinical context, supporting Risorius' internal R&D, model development, and validation efforts.

Why it matters

This agreement highlights the growing demand for high-quality, regulatory-grade real-world data to power the development of innovative digital biomarkers and advanced analytics solutions for central nervous system disorders. It also demonstrates OneMedNet's ability to serve as a trusted infrastructure partner enabling AI innovation in the healthcare industry.

The details

Under the agreement, Risorius has licensed access to OneMedNet's diverse multimodal data, including high-fidelity EEG and PSG waveforms paired with longitudinal clinical data. This data will support Risorius' efforts to advance EEG-based digital biomarkers and an AI Co-Scientist platform designed to aid neurological and psychiatric clinical studies. Risorius selected OneMedNet based on the strong fit for its R&D requirements, including access to substantial data volume, a transparent curation process, and a well-organized de-identification workflow.

  • The agreement was executed in record time following the companies' initial meeting.
  • Data delivery is now underway and will be continuously delivered over a three-month project under the licensing agreement.

The players

OneMedNet Corporation

A leading provider of regulatory-grade, AI-ready Real-World Data (RWD).

Risorius Co., Ltd.

A neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep.

Aaron Green

CEO and President of OneMedNet.

Sangyoon Bae

CEO of Risorius.

Got photos? Submit your photos here. ›

What they’re saying

“Risorius' rapid decision to partner with OneMedNet underscores the value of our regulatory-grade neuro data and continuous delivery model. Real-World EEG and PSG waveform data, when paired with longitudinal clinical results, are foundational to the research and development of next-generation solutions focused on solving central nervous system disorders.”

— Aaron Green, CEO and President of OneMedNet (OneMedNet)

“We chose OneMedNet because of the clear alignment with our scientific and operational needs. The combination of well-curated EEG and PSG waveform data, meaningful longitudinal follow-up, and a scalable licensing model provides the foundation we need to accelerate internal R&D, model validation, and development of our AI Co-Scientist platform.”

— Sangyoon Bae, CEO of Risorius (Risorius)

What’s next

The partnership highlights continued momentum in OneMedNet's data licensing strategy, and the efficient commercial execution demonstrated by rapid contract conversion indicates OneMedNet is positioned as a trusted infrastructure partner enabling AI innovation.

The takeaway

This agreement underscores the growing importance of high-quality, regulatory-grade real-world data in powering the development of innovative digital biomarkers and advanced analytics solutions for central nervous system disorders. It also demonstrates OneMedNet's ability to serve as a trusted partner for AI-driven companies seeking scalable, curated datasets to accelerate their research and development efforts.